Travere Therapeutics Announces Pricing of Public Offering of Common Stock
Summary
We are a biopharmaceutical company that comes together every day to help patients, families and caregivers of all backgrounds as they navigate life with a rare disease. On this path, we know the need for treatment options is urgent that is why our global team works with the rare disease community to identify, develop and deliver life-changing therapies. In pursuit of this mission, we continuously seek to understand the diverse perspectives of rare patients and to courageously forge new paths to make a difference in their lives and provide hope today and tomorrow.Certain statements in this press release are forward-looking statements that involve a number of risks and uncertainties. Factors that could cause actual results to differ materially from the forward-looking statements include, but are not limited to, risks and uncertainties associated with market conditions and the satisfaction of customary closing conditions related to the proposed offering, and those factors disclosed in Traveres filings with the SEC, including its Quarterly Report on Form 10-Q for the quarter ended September 30, 2024. Travere disclaims any intent or obligation to update these forward-looking statements, other than as may be required under applicable law.